Drugs /

multi-epitope her2 peptide vaccine h2nvac

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for multi-epitope her2 peptide vaccine h2nvac

Multi-epitope her2 peptide vaccine h2nvac has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating multi-epitope her2 peptide vaccine h2nvac, 1 is phase 1 (1 open).

ERBB2 Amplification, HER2 Deficient Expression, and HER2 Expression are the most frequent biomarker inclusion criteria for multi-epitope her2 peptide vaccine h2nvac clinical trials.

Ductal carcinoma in situ is the most common disease being investigated in multi-epitope her2 peptide vaccine h2nvac clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Multi-Epitope Her2 Peptide Vaccine H2nvac
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating multi-epitope her2 peptide vaccine h2nvac and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
ERBB2

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.